基蛋生物(603387) - 2023 Q3 - 季度财报

Financial Performance - Q3 2023 revenue was CNY 297,605,041.36, a decrease of 26.33% year-over-year[2] - Net profit attributable to shareholders was CNY 60,349,670.97, down 58.49% compared to the same period last year[2] - Basic earnings per share for Q3 2023 was CNY 0.12, reflecting a decline of 58.62% year-over-year[2] - In Q3 2023, the company reported a revenue of RMB 1.001 billion, a decrease of 27.32% compared to the same period last year[11] - The net profit attributable to shareholders was RMB 229 million, down 51.80% year-on-year, while the net profit excluding non-recurring items was RMB 198 million, a decrease of 56.84%[11] - Total operating revenue for the first three quarters of 2023 was CNY 1,000,961,989.28, a decrease of 27.3% compared to CNY 1,377,167,848.88 in the same period of 2022[19] - Net profit for the first three quarters of 2023 was CNY 233,662,791.59, a decline of 51.4% from CNY 481,071,216.93 in the same period of 2022[20] - The company reported a profit before tax of CNY 249,393,861.89 for the first three quarters of 2023, down 53.8% from CNY 539,806,744.44 in the same period of 2022[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,767,784,884.31, an increase of 2.46% from the end of the previous year[3] - As of September 30, 2023, total assets amounted to RMB 3.768 billion, compared to RMB 3.677 billion at the end of 2022[15] - Total liabilities as of the end of the third quarter of 2023 amounted to CNY 1,088,462,214.02, compared to CNY 1,012,840,595.85 at the end of the previous year[17] - Total equity as of the end of the third quarter of 2023 was CNY 2,679,322,670.29, an increase from CNY 2,664,597,352.39 at the end of the previous year[17] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 146,507,664.68, a decrease of 29.52%[2] - Operating cash flow for the first nine months of 2023 was CNY 146,507,664.68, a decrease of 29.4% compared to CNY 207,880,331.23 in the same period of 2022[25] - Cash inflow from operating activities totaled CNY 1,268,627,997.86, while cash outflow was CNY 1,122,120,333.18, resulting in a net cash flow from operating activities of CNY 146,507,664.68[25] - Cash and cash equivalents decreased to RMB 410.16 million from RMB 646.25 million at the end of 2022[14] - The total cash and cash equivalents at the end of the period was CNY 407,471,086.12, down from CNY 1,133,577,261.76 at the beginning of the period[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,255[8] - The largest shareholder, Su Enben, holds 39.77% of the shares, totaling 201,670,295 shares[8] Product and Market Performance - The company's self-produced product revenue reached RMB 766.21 million, an increase of 29.31% year-on-year, with the POCT (excluding COVID-19) segment generating RMB 531.05 million, up 14.83%[12] - The core product Getein1600 saw steady growth with over 660 units installed in the first three quarters of 2023, reinforcing the company's leading position in the POCT field[12] - The MAGICL6000 product line achieved nearly 800 units installed in Q3 2023, with a cumulative installation of nearly 1,700 units, contributing to a significant revenue increase of 156.48% in the chemiluminescence segment[12] - The company launched the self-developed Metis6000 fully automated immunoassay line in Q1 2023, with nearly 40 units installed by Q3, over 50% of which are in secondary hospitals or above[12] Cost Management and Future Plans - Total operating costs for the first three quarters of 2023 were CNY 779,963,522.08, down 8.0% from CNY 847,993,776.91 in the previous year[19] - Research and development expenses for the first three quarters of 2023 were CNY 160,651,078.79, an increase of 5.0% compared to CNY 151,894,491.01 in the previous year[19] - The company continues to focus on conventional business and market expansion while enhancing cost control and efficiency[12] - The company plans to continue focusing on market expansion and new product development in the upcoming quarters[18]